Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been
widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Many studies have attempted to explain the interindividual variability observed in drug
metabolism by assessing the impact of SNPs in genes implicated in drug absorption, distribution, …

Background The European Randomised study of Screening for Prostate Cancer (ERSPC)
has shown significant reductions in prostate cancer mortality after 9 years and 11 years of …

Background The calcineurin inhibitors cyclosporine (INN, ciclosporin) and tacrolimus have
a narrow therapeutic index and show considerable interindividual variability in their …

Purpose : Prostate specific antigen and free prostate specific antigen have limited specificity
to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and …

Background: Enzymes of the cytochrome P450 3A (CYP3A) family are responsible for the
metabolism of >50% of currently prescribed drugs. CYP3A5 is expressed in a limited number …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

BACKGROUND: Novel markers for prostate cancer (PCa) detection are needed. Total
prostate-specific antigen (tPSA) and percent free prostate-specific antigen (%fPSA=tPSA/fPSA) …

Purpose : The Prostate Health Index (phi) is a new test combining total, free and [-2]proPSA
into a single score. It was recently approved by the FDA and is now commercially available …